FDA clears Parvoviris B19 tests by Biotrin

The US Food and Drug Administration (FDA) have cleared for sale in the US the propriety Parvovirus B19 tests made by Irish-based company Biotrin International.

The FDA approved the Biotrin tests for pregnant women suspected of exposure to Parvovirus B19 and for Fifth Disease, a common childhood illness.

The Parvovirus B19 infection is a common but mild illness, similar to rubella infection. However, in pregnant women it can cause miscarriages and foetal infection.

"The achievement represents a milestone for Biotrin, as it is our first FDA approval and it is a testament to the great efforts of our dedicated staff and our team of clinical regulatory advisors," said Dr Cormac Kilty, President of Biotrin International.

Biotrin has its manufacturing, research and development, and marketing facilities in Dublin.